Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients with Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
Inclusion Criteria
- Patients must have a locally advanced and unresectable or metastatic gastroenteropancreatic neuroendocrine carcinoma that is either known or suspected to be of gastrointestinal (GI) origin; primary tumors arising from the lung, gynecologic organs or prostate are not permitted
- Patients must have pathologically/histologically confirmed tumor of non-small cell histology
- Patients must have a Ki-67 proliferative index of 20-100% OR at least 10 mitotic figures per 10 high powered fields
- Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained within 4 weeks prior to randomization and must be acquired by multiphasic computed tomography (CT) or contrast magnetic resonance imaging (MRI) * NOTE: positron emission tomography (PET)-CT scans are allowed provided the CT portion of the exam is equivalent to a diagnostic CT scan and includes both oral and IV contrast
- Patients may not have had any prior systemic treatment (chemotherapy, targeted therapy, peptide receptor radionuclide therapy [PRRT]); prior palliative radiation is permitted but radiated lesions may not be used for measurement
- Patients may not have received any of the protocol agents within 5 years prior to randomization
- Any prior surgeries must have been completed at least 4 weeks prior to randomization
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Patients may not be receiving any other investigational agents while on study treatment
- Patients may not be receiving Coumadin while on treatment; other anticoagulants are allowed
- Leukocytes >= 3,000/mm^3 (within less than or equal to 14 days prior to randomization)
- Absolute neutrophil count >= 1,500/mm^3 (within less than or equal to 14 days prior to randomization)
- Hemoglobin >= 9 g/dL (within less than or equal to 14 days prior to randomization)
- Platelets >= 100,000/mm^3 (within less than or equal to 14 days prior to randomization)
- Total bilirubin =< institutional upper limit of normal (ULN) or =< 1.5 x institutional ULN (if the patient has liver metastases) (within less than or equal to 14 days prior to randomization)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN or (=< 5 x institutional ULN if the patient has liver metastases) (within less than or equal to 14 days prior to randomization)
- Serum creatinine =< 1.5 x institutional ULN and creatinine clearance >= 60 ml/min (within less than or equal to 14 days prior to randomization) * NOTE: creatinine clearance must be calculated using the Cockcroft-Gault equation
- Patients must have a life expectancy of >= 12 weeks as determined clinically by the treating physician
- Patients with brain metastases (either remote or current) or presence of carcinomatous meningitis are not eligible
- Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency will be excluded as the use of capecitabine is contraindicated in these patients
- Patients must NOT have active or uncontrolled infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia or a serious psychiatric illness/social situation that would limit compliance with study requirements
- Patients with impaired decision making capacity may participate in the study if a legal authorized representative is available to consent
- Patients must NOT have a history of allergic reactions attributed to compounds of similar chemical or biochemical composition to cisplatin, carboplatin, etoposide, temozolomide or capecitabine
- Patients must NOT have absorption issues that would limit the ability to absorb study agents
- Patients with a history of the following within =< 12 months of study entry are not eligible: * Arterial thromboembolic events * Unstable angina * Myocardial Infarction
- Patients with symptomatic peripheral vascular disease are not eligible
- Patients must NOT have previous or concurrent malignancy; exceptions are made for patients who meet any of the following conditions: * Non-melanoma skin cancer, in situ cervical cancer, superficial bladder cancer, or breast cancer in situ OR * Prior malignancy completely excised or removed and patient has been continuously disease free for > 5 years OR * Prior malignancy cured by non-surgical modalities and patient has been continuously disease free for > 5 years
- Women must not be pregnant or breast-feeding due to potential harm to the fetus from cisplatin, carboplatin, etoposide, temozolomide and/or capecitabine * All females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy * A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
- Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for the duration of their participation in the study
- Patients must be able to swallow pills
- Patients must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for the treatment and the protocol
- Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with cisplatin, carboplatin, etoposide, temozolomide, and/or capecitabine; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
Arizona
Kingman
Phoenix
Arkansas
Ft. Smith
Hot Springs
California
Antioch
Arroyo Grande
Auburn
Berkeley
Burlingame
Cameron Park
Castro Valley
Davis
Dublin
Fremont
Fresno
Los Angeles
Modesto
Mountain View
Newport Beach
Novato
Oakland
Palo Alto
Pasadena
Rancho Mirage
Redwood City
Richmond
Roseville
Sacramento
San Francisco
San Jose
San Leandro
San Luis Obispo
San Rafael
Santa Clara
Santa Cruz
Santa Maria
Santa Rosa
South San Francisco
Stockton
Sunnyvale
Vacaville
Vallejo
Walnut Creek
Colorado
Aurora
Colorado Springs
Denver
Durango
Golden
Lakewood
Littleton
Longmont
Parker
Pueblo
Thornton
Delaware
Frankford
Lewes
Newark
Rehoboth Beach
Seaford
Wilmington
District of Columbia
Washington
Florida
Fort Lauderdale
Georgia
Atlanta
Johns Creek
Macon
Hawaii
Honolulu
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Meridian
Nampa
Post Falls
Sandpoint
Illinois
Aurora
Bloomington
Burr Ridge
Canton
Carbondale
Carterville
Carthage
Centralia
Chicago
Danville
DeKalb
Decatur
Dixon
Effingham
Eureka
Galesburg
Geneva
Homer Glen
Kewanee
Lake Forest
Macomb
Mattoon
Maywood
Melrose Park
Mount Vernon
New Lenox
O'Fallon
Orland Park
Ottawa
Pekin
Peoria
Peru
Princeton
Springfield
Swansea
Urbana
Warrenville
Yorkville
Indiana
Evansville
Michigan City
Newburgh
Richmond
Iowa
Ames
Boone
Clive
Council Bluffs
Creston
Des Moines
Fort Dodge
Jefferson
Marshalltown
Sioux City
West Des Moines
Kansas
Chanute
Coffeyville
Dodge City
El Dorado
Fort Scott
Garden City
Great Bend
Hays
Independence
Kansas City
Kingman
Lawrence
Lenexa
Liberal
Manhattan
McPherson
Newton
Olathe
Overland Park
Parsons
Pittsburg
Pratt
Salina
Topeka
Wellington
Westwood
Wichita
Winfield
Kentucky
Bardstown
Corbin
Crestview Hills
Lexington
London
Louisville
Shepherdsville
Louisiana
Alexandria
Baton Rouge
Kenner
Lake Charles
Monroe
New Orleans
Shreveport
Maryland
Baltimore
Randallstown
Westminster
Massachusetts
Boston
Springfield
Michigan
Ann Arbor
Battle Creek
Brighton
Brownstown
Canton
Caro
Chelsea
Clarkston
Clinton Township
Dearborn
Detroit
East China
Farmington Hills
Flint
Grand Rapids
Grosse Pointe Woods
Jackson
Kalamazoo
Lansing
Livonia
Macomb Township
Marlette
Monroe
Muskegon
Niles
Norton Shores
Novi
Pontiac
Port Huron
Reed City
Rochester Hills
Saginaw
Saint Joseph
Shelby Township
Sterling Heights
Tawas City
Traverse City
Warren
West Bloomfield
West Branch
Wyoming
Ypsilanti
Minnesota
Bemidji
Burnsville
Cambridge
Coon Rapids
Edina
Fridley
Maple Grove
Maplewood
Minneapolis
Monticello
New Ulm
Princeton
Robbinsdale
Rochester
Saint Louis Park
Saint Paul
Shakopee
Stillwater
Thief River Falls
Waconia
Willmar
Woodbury
Worthington
Wyoming
Missouri
Ballwin
Bolivar
Bonne Terre
Branson
Cape Girardeau
Creve Coeur
Farmington
Independence
Jefferson City
Joplin
Kansas City
Lee's Summit
Rolla
Saint Joseph
Saint Louis
Saint Peters
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Washington
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Helena
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Lincoln
Omaha
Papillion
Nevada
Carson City
Henderson
Las Vegas
Pahrump
Reno
New Hampshire
Lebanon
New Jersey
Mullica Hill
Vineland
New Mexico
Albuquerque
New York
Bronx
New York
North Carolina
Asheville
Cary
Clinton
Clyde
Durham
Goldsboro
Hendersonville
Jacksonville
Raleigh
Washington
North Dakota
Bismarck
Fargo
Ohio
Beachwood
Beavercreek
Belpre
Boardman
Centerville
Chardon
Chillicothe
Cincinnati
Cleveland
Columbus
Dayton
Delaware
Dublin
Elyria
Fairfield
Findlay
Franklin
Greenville
Grove City
Independence
Kettering
Lancaster
Mansfield
Marietta
Marion
Mayfield Heights
Mentor
Middleburg Heights
Middletown
Mount Vernon
Newark
Parma
Portsmouth
Sandusky
Sidney
Springfield
Strongsville
Sylvania
Toledo
Troy
Wadsworth
Warren
Warrensville Heights
West Chester
Westerville
Westlake
Wooster
Youngstown
Zanesville
Oklahoma
Lawton
Oklahoma City
Oregon
Baker City
Ontario
Pennsylvania
Allentown
Beaver
Bethlehem
Chadds Ford
Danville
East Stroudsburg
Greensburg
Hazleton
Hershey
Johnstown
Lewisburg
Lewistown
McKeesport
Moon Township
Philadelphia
Pittsburgh
Pottsville
Scranton
Selinsgrove
Seneca
State College
Uniontown
Washington
Wilkes-Barre
South Carolina
Anderson
Boiling Springs
Charleston
Easley
Greenville
Greer
Seneca
South Dakota
Sioux Falls
Tennessee
Chattanooga
Hixson
Ooltewah
Texas
Bryan
Dallas
Fort Worth
Houston
Richardson
San Antonio
Sugar Land
Utah
Farmington
Salt Lake City
Washington
Bellevue
Bremerton
Burien
Enumclaw
Federal Way
Lakewood
Poulsbo
Renton
Tacoma
Wisconsin
Burlington
Chippewa Falls
Eau Claire
Fond Du Lac
Germantown
Grafton
Green Bay
Johnson Creek
Kenosha
Ladysmith
Madison
Marinette
Marshfield
Milwaukee
Minocqua
New Richmond
Oshkosh
Racine
Rice Lake
Sheboygan
Stevens Point
Summit
Two Rivers
Waukesha
Wausau
Wauwatosa
West Allis
Weston
Wisconsin Rapids
Wyoming
Cody
Sheridan
PRIMARY OBJECTIVE:
I. To assess the progression free survival (PFS) of platinum (cisplatin or carboplatin) and etoposide versus the PFS of temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas.
SECONDARY OBJECTIVES:
I. To assess the response rate (RR) of platinum (cisplatin or carboplatin) and etoposide versus the RR of temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas.
II. To assess the overall survival (OS) of platinum (cisplatin or carboplatin) and etoposide versus the OS of temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas.
III. To evaluate the toxicities associated with the combination of temozolomide and capecitabine and the combination of platinum (cisplatin or carboplatin) and etoposide, respectively, in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas.
LABORATORY RESEARCH OBJECTIVES:
I. To assess the impact of each treatment regimen on PFS, RR and OS based on marker Ki-67 index in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas.
II. To assess the prognostic significance of well differentiated versus poorly differentiated non-small cell gastroenteropancreatic neuroendocrine tumors in relationship to survival and response to treatment.
III. To assess the agreement in Ki-67 status between that reported by institutional pathologist and that reported by central pathology review.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14 and temozolomide PO once daily (QD) on days 10-14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive cisplatin intravenously (IV) on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, then every 3 months for 2 years and then every 6 months for 3 years.
Trial Phase Phase II
Trial Type Treatment
Lead Organization
ECOG-ACRIN Cancer Research Group
Principal Investigator
Jennifer Rachel Eads
- Primary ID EA2142
- Secondary IDs NCI-2015-00547
- Clinicaltrials.gov ID NCT02595424